A recent report indicated that coadministration of PARPi niraparib and anti-PD-1 enhanced the infiltration of immune cells into tumor microenvironment and increased synergistic antitumor activities in both immunocompetent BRCA-proficient and BRCA-deficient models, including breast cancer, lung squamous cell carcinoma, colon adenocarcinoma, bladder cancer, and sarcoma [148]. The gene discussed is PDCD1; the disease is neoplasm.